Literature DB >> 28868263

Next Generation Sequencing and Association Studies in Familial Nonmedullary Thyroid Carcinoma: Let's Choose Appropriate Controls.

Laure Cazabat1,2, Aglae Terray1, Philippe de Mazancourt3, Jacques Ropers4, Lionel Groussin5,6, Marie-Laure Raffin-Sanson1,2.   

Abstract

Entities:  

Year:  2017        PMID： 28868263      PMCID： PMC5567105          DOI： 10.1159/000477492

Source DB:  PubMed          Journal:  Eur Thyroid J        ISSN： 2235-0640


× No keyword cloud information.
  14 in total

1.  HABP2 Mutation and Nonmedullary Thyroid Cancer.

Authors:  Sudheer Kumar Gara; Electron Kebebew
Journal:  N Engl J Med       Date:  2015-11-19       Impact factor: 91.245

2.  HABP2 Mutation and Nonmedullary Thyroid Cancer.

Authors:  Ximeng Zhao; Xiaoyi Li; Xue Zhang
Journal:  N Engl J Med       Date:  2015-11-19       Impact factor: 91.245

3.  HABP2 in Familial Non-medullary Thyroid Cancer: Will the Real Mutation Please Stand Up?

Authors:  Joanne Ngeow; Charis Eng
Journal:  J Natl Cancer Inst       Date:  2016-02-01       Impact factor: 13.506

4.  HABP2 Gene Mutations Do Not Cause Familial or Sporadic Non-Medullary Thyroid Cancer in a Highly Inbred Middle Eastern Population.

Authors:  Ali S Alzahrani; Avaniyapuram Kannan Murugan; Ebtesam Qasem; Hindi Al-Hindi
Journal:  Thyroid       Date:  2016-04-08       Impact factor: 6.568

5.  HABP2 G534E variation in familial non-medullary thyroid cancer: an Italian series.

Authors:  S Cantara; C Marzocchi; M G Castagna; F Pacini
Journal:  J Endocrinol Invest       Date:  2016-11-21       Impact factor: 4.256

6.  Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism.

Authors:  Berthold Hoppe; Farzaneh Tolou; Hartmut Radtke; Holger Kiesewetter; Thomas Dörner; Abdulgabar Salama
Journal:  Blood       Date:  2004-10-14       Impact factor: 22.113

7.  The HABP2 G534E variant is an unlikely cause of familial non-medullary thyroid cancer.

Authors:  Ruta Sahasrabudhe; Jacob Stultz; John Williamson; Paul Lott; Ana Estrada; Mabel Bohorquez; Claire Palles; Guadalupe Polanco-Echeverry; Emma Jaeger; Lynn Martin; Maria Magdalena Echeverry; Ian Tomlinson; Luis G Carvajal-Carmona
Journal:  J Clin Endocrinol Metab       Date:  2015-12-21       Impact factor: 5.958

8.  Factor VII Activating Protease Polymorphism (G534E) Is Associated with Increased Risk for Stroke and Mortality.

Authors:  Stella Trompet; Douwe Pons; Sandip M Kanse; Anton J M de Craen; M Arfan Ikram; Jeffrey J W Verschuren; Aeilko H Zwinderman; Pieter A F M Doevendans; René A Tio; Robbert J de Winter; P Eline Slagboom; Rudi G J Westendorp; J Wouter Jukema
Journal:  Stroke Res Treat       Date:  2011-06-30

9.  HABP2 G534E Variant in Papillary Thyroid Carcinoma.

Authors:  Jerneja Tomsic; Rebecca Fultz; Sandya Liyanarachchi; Huiling He; Leigha Senter; Albert de la Chapelle
Journal:  PLoS One       Date:  2016-01-08       Impact factor: 3.240

10.  The HABP2 G534E polymorphism does not increase nonmedullary thyroid cancer risk in Hispanics.

Authors:  Mabel E Bohórquez; Ana P Estrada; Jacob Stultz; Ruta Sahasrabudhe; John Williamson; Paul Lott; Carlos S Duque; Jorge Donado; Gilbert Mateus; Fernando Bolaños; Alejandro Vélez; Magdalena Echeverry; Luis G Carvajal-Carmona
Journal:  Endocr Connect       Date:  2016-04-20       Impact factor: 3.335
View more
  2 in total

Review 1.  Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates.

Authors:  José Manuel Cameselle-Teijeiro; Ozgur Mete; Sylvia L Asa; Virginia LiVolsi
Journal:  Endocr Pathol       Date:  2021-01-25       Impact factor: 3.943

Review 2.  Susceptibility Genes and Chromosomal Regions Associated With Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Some Pathogenetic and Diagnostic Keys.

Authors:  María Sánchez-Ares; Soledad Cameselle-García; Ihab Abdulkader-Nallib; Gemma Rodríguez-Carnero; Carolina Beiras-Sarasquete; José Antonio Puñal-Rodríguez; José Manuel Cameselle-Teijeiro
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-28       Impact factor: 5.555
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.